|
1.
|
|
14 p, 2.8 MB |
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis : Pooled Data from Two Phase III Trials
/
Simpson, Eric L. (Oregon Health and Science University) ;
Pink, Andrew E. (Guy's and St, Thomas' NHS Foundation Trust) ;
Blauvelt, Andrew (Oregon Medical Research Center) ;
Gooderham, Melinda (Centre for Dermatology and Probity Medical Research) ;
Armstrong, April W. (University of Southern California) ;
Worm, Margitta (Universitätsmedizin Berlin) ;
Katoh, Norito (Kyoto Prefectural University of Medicine) ;
Peris, Ketty (Catholic University of the Sacred Heart) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Barbarot, Sébastien (University Hospital of Nantes) ;
Mark, Thomas (LEO Pharma A/S) ;
Steffensen, Louise Abildgaard (LEO Pharma A/S) ;
Tindberg, Ann-Marie (LEO Pharma A/S) ;
Wollenberg, Andreas (University Hospital Brussels) ;
Universitat Autònoma de Barcelona
Two phase III trials, ECZTRA 1 and 2, confirmed the efficacy and safety of tralokinumab versus placebo in adults with moderate-to-severe atopic dermatitis (AD). To further explore the long-term efficacy of tralokinumab for AD, a pooled analysis of these trials was conducted. [...]
2023 -  10.1007/s40257-023-00806-3
American Journal of Clinical Dermatology, Vol. 24 (september 2023) , p. 939-952
|
|
|
2.
|
|
11 p, 1.8 MB |
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks : A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
/
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Costanzo, Antonio (Humanitas Clinical and Research Center IRCCS) ;
de Jong, Elke M. G. J. (Radboud University Medical Center) ;
Torres, Tiago (University of Porto) ;
Warren, Richard B. (The University of Manchester) ;
Wapenaar, Robert (Janssen-Cilag BV (Breda, Països Baixos)) ;
Wegner, Sven (Janssen-Cilag GmbH (Neuss, Alemanya)) ;
Gorecki, Patricia (Janssen-Cilag Ltd (High Wycombe, Regne Unit)) ;
Gramiccia, Talia (Janssen-Cilag SpA (Milà, Itàlia)) ;
Jazra, Maria (Janssen-Cilag (París, França)) ;
Buyze, Jozefien (Janssen Pharmaceutica NV (Beerse, Bèlgica)) ;
Conrad, Curdin (University of Lausanne) ;
Universitat Autònoma de Barcelona
Treatment of moderate-to-severe plaque psoriasis with biologics, such as guselkumab, has demonstrated greater efficacy over traditional non-biologic treatments. However, given patient diversity, greater understanding of the relationship between patient characteristics, positive clinical outcomes, and long-term response to biologics is crucial for optimizing treatment choices. [...]
2023 - 10.1007/s40257-023-00816-1
American Journal of Clinical Dermatology, Vol. 25 (october 2023) , p. 315-325
|
|
|
3.
|
|
10 p, 673.5 KB |
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors : A Retrospective, Multinational, Multicentre Study
/
Torres, Tiago (University of Porto, Portugal) ;
Chiricozzi, Andrea (Università Cattolica del Sacro Cuore, Rome, Italy) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Lé, Ana Maria (Centro Académico Clínico ICBAS - CHP, Porto, Portugal) ;
Marzano, Angelo Valerio (Università degli Studi di Milano, Italy) ;
Dapavo, Paolo (University of Turin, Italy) ;
Dauden, Esteban (Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP), Madrid) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Lazaridou, Elizabeth (Aristotle University School of Medicine, Thessaloniki, Greece) ;
Duarte, Gleison (Instituto Bahiano de Imunoterapias-IBIS, Salvador, Brazil) ;
Carvalho, André V. E. (Hospital Moinhos de Vento, Porto Alegre, Brazil) ;
Romiti, Ricardo (University of São Paulo, Brazil) ;
Rompoti, Natalia (University of Athens, 'A. Sygros' Hospital for Skin and Venereal Diseases, Athens, Greece) ;
Teixeira, Laetitia (Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal) ;
Abreu, Miguel (University of Porto, Portugal) ;
Ippoliti, Elena (Università Cattolica del Sacro Cuore, Rome, Italy) ;
Maronese, Carlo Alberto (Università degli Studi di Milano, Italy) ;
Llamas-Velasco, Mar (Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP)) ;
Vilarrasa-Rull, Eva (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
del Alcázar, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Daponte, Athina-Ioanna (Aristotle University School of Medicine, Thessaloniki, Greece) ;
Papoutsaki, Marina (University of Athens, 'A. Sygros' Hospital for Skin and Venereal Diseases, Athens, Greece) ;
Carugno, Andrea (ASST Papa Giovanni XXIII, Bergamo, Italy) ;
Bellinato, Francesco (University Hospital of Verona (Itàlia)) ;
Gisondi, Paolo (University Hospital of Verona (Itàlia)) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of tuberculosis reactivation, current guidelines recommend tuberculosis screening before starting any biologic drug, and chemoprophylaxis if LTBI is diagnosed. [...]
2024 - 10.1007/s40257-024-00845-4
American Journal of Clinical Dermatology, Vol. 25, Num. 2 (march 2024) , p. 333-342
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
14 p, 1.3 MB |
Infections in Dupilumab Clinical Trials in Atopic Dermatitis : A Comprehensive Pooled Analysis
/
Eichenfield, Lawrence (Division of Pediatric and Adolescent Dermatology. Rady Children's Hospital) ;
Bieber, T. (Department of Dermatology and Allergy. Christine Kühne-Center for Allergy Research and Education. University of Bonn) ;
Beck, Lisa (University of Rochester Medical Center. Department of Dermatology) ;
Simpson, E. L. (Oregon Health and Science University. Department of Dermatology) ;
Thaçi, Diamant (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
de Bruin-Weller, Marjolein (University Medical Center Utrecht) ;
Deleuran, Mette (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Silverberg, J. I. (Northwestern University Feinberg School of Medicine) ;
Ferrándiz, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fölster-Holst, R. (University Hospital Schleswig-Holstein. Dermatology) ;
Chen, Z. (Regeneron Pharmaceuticals. Inc.) ;
Graham, N. M. H. (Regeneron Pharmaceuticals. Inc.) ;
Pirozzi, G. (Sanofi) ;
Akinlade, Bolanle (Regeneron Pharmaceuticals. Inc.) ;
Yancopoulos, G. D. (Regeneron Pharmaceuticals. Inc.) ;
Ardeleanu, Marius (Regeneron Pharmaceuticals. Inc.) ;
Universitat Autònoma de Barcelona
Background: Patients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e. g. , anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus kinase inhibitors) increase risk of infections. [...]
2019 - 10.1007/s40257-019-00445-7
American Journal of Clinical Dermatology, Vol. 20 Núm. 3 (january 2019) , p. 443-456
|
|
|
7.
|
|
1 p, 320.3 KB |
Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
/
Blauvelt, Andrew (SW Locust St., Suite G, Portland, OR 97223 USA) ;
Papp, Kim A. (Waterloo, Canada) ;
Griffiths, Christopher E. M. (Manchester, UK) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ;
Dutronc, Yves (Indianapolis, IN USA) ;
Kerr, Lisa Farmer (Indianapolis, IN USA) ;
Ilo, Dapo (Indianapolis, IN USA) ;
Mallbris, Lotus (Indianapolis, IN USA) ;
Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ;
Universitat Autònoma de Barcelona
2018 - 10.1007/s40257-018-0353-x
American Journal of Clinical Dermatology, Vol. 19 (march 2018) , p. 457
|
|
|
8.
|
|
8 p, 420.3 KB |
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders : a Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
/
Blauvelt, Andrew (SW Locust St., Suite G, Portland, USA) ;
Papp, Kim A. (Waterloo, Canada) ;
Griffiths, Christopher E. M. (Manchester, UK) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ;
Dutronc, Yves (Indianapolis, IN USA) ;
Kerr, Lisa Farmer (Indianapolis, IN USA) ;
Ilo, Dapo (Indianapolis, IN USA) ;
Mallbris, Lotus (Indianapolis, IN USA) ;
Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ;
Universitat Autònoma de Barcelona
Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. [...]
2017 - 10.1007/s40257-016-0246-9
American Journal of Clinical Dermatology, Vol. 18 (january 2017) , p. 273-280
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
